Author + information
- Paul A. Gurbel,
- Kevin Bliden,
- Christopher Franzese,
- Martin Gesheff,
- Himabindu Kaza,
- Udaya Tantry and
- William Harris
The polyunsaturated long chain omega-3 fatty acids, EPA and DHA may reduce cardiovascular disease (CVD) risk. We sought to determine the extent to which plasma levels of EPA and DHA reflect the amount of fish oil consumed based on patient report.
Plasma fatty acid composition in 437 patients with suspected coronary artery disease undergoing cardiac catheterization was analyzed using gas chromatography. Information on medication and supplement use was collected from medical charts and patient interview. Correlation between the plasma EPA+DHA level and reported number of fish oil capsules was determined in 101 patients taking fish oil supplementation (FOS). An additional comparison between serum and RBC EPA + DHA (Omega-3 index) was performed in 50 random patient samples.
Patients reporting FOS use had greater plasma EPA+DHA (3.9±1.5 vs. 2.5±0.9 % of total identified fatty acids, p<0.0001) than patients not on FOS. There was a strong correlation between serum EPA+DHA and Omega-3 index (R=0.88, p<0.001), with FOS users corresponding to an Omega-3 Index of approximately 7%. No relation between reported daily intake of FOS and plasma EPA+DHA was observed (figure).
There is no relationship between the number of fish oil pills patients report taking and plasma EPA+DHA. The latter may be related to varying amounts of fatty acid per capsule and absorption. Objective measurement of plasma or RBC EPA+DHA is required to optimize fish oil supplementation.
Poster Hall B1
Sunday, March 15, 2015, 9:45 a.m.-10:30 a.m.
Session Title: Lipids and Lipid Lowering in Stable Ischemic Heart Disease
Abstract Category: 27. Stable Ischemic Heart Disease: Therapy
Presentation Number: 1194-363
- 2015 American College of Cardiology Foundation